BGBing Gao

Bing Gao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Bing Gao has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Association between hepatic steatosis index and female infertility: a cross-sectional study using NHANES 2013–2018

    by Yaping Wang, Wenxuan Zhang, Yuxiang Cao, Ping Gong, Qingling Li, Jing Wang, Bing Gao

    Female infertility is a major reproductive health concern worldwide and is commonly defined as the inability to achieve a clinical pregnancy after 12 months of regular unprotected sexual intercours...

  • Association of the C-reactive protein-triglyceride-glucose (CTI) index with asthma prevalence: Evidence from dual national cohorts

    by Wenxuan Zhang, Liya Li, Shuting Du, Yaping Wang, Yuxiang Cao, Chengyun Hu, Jing Wang, Bing Gao


  • Open Access

    The relationship between hepatic steatosis index and hypertension: NHANES 2011–2018

    by Wenxuan Zhang, Bing Gao, Yaping Wang, Yuxiang Cao, Jing Wang

    The Hepatic Steatosis Index (HSI) serves as a non-invasive indicator for assessing liver fat accumulation. Its potential association with hypertension has garnered increasing attention, as metabolic dysfunctions, including hepatic steatosis, may contribute to elevated blood pressure via mechanisms such as insulin resistance and chronic inflammation. Utilizing data from the NHANES database (2011–2018), the HSI was calculated on the basis of alanine aminotransferase (ALT), aspartate aminotransferase (AST) and BMI.The association between HSI and hypertension was assessed by univariate analysis, weighted multivariate Logistic regression, and restricted cubic spline (RCS) models. Subgroup analyses were performed to increase the reliability of the data. This cross-sectional study analysed data from 17,501 adults (NHANES 2011–2018) to assess the association between HSI and hypertension. Of these, 9,890 (56.51%) were diagnosed with hypertension.In the unadjusted model, HSI demonstrated a statistically significant correlation with hypertension, showing an odds ratio (OR) of 1.05 (95% confidence interval: 1.04–1.06).After adjustment for potential confounders, a higher prevalence of hypertension was observed in participants in the upper HSI quartiles (Q3 and Q4), with corresponding ORs of 2.29 (95% CI: 2.29–2.63) and 4.03 (95% CI: 3.42–4.74), respectively. RCS analysis revealed a U-shaped non-linear relationship between HSI and hypertension (P < 0.001), indicating that while hypertension risk primarily escalated with increasing HSI, a modest risk elevation was also detected at lower HSI levels. This suggests that both excessive liver fat accumulation (indicated by a high HSI) and underlying metabolic disorders (such as malnutrition or sarcopenia) may contribute to hypertension risk in individuals with unexpectedly low HSI. Subgroup analyses identified significant interactions in relation to education, cancer, and diabetes mellitus (p for interaction < 0.05), whereas no significant interactions were observed in other stratifications. This study found a U-shaped relationship between the hepatic steatosis index (HSI) and the risk of hypertension. Although the HSI shows potential as a practical screening tool in primary care, further longitudinal studies are needed to establish causality and explore the complex bidirectional pathways involved. Not applicable.


  • Open Access

    Network pharmacology and in vitro experiments reveal the autophagy mechanism of Yanggan-Yishui granules in improving hypertensive renal injury

    by Pan Liu, Tairan Hu, Bing Gao, Ran Xia, Xiaohua Dai, Jing Wang

    Introduction: In China, Yanggan-Yishui granules (YGYSG) have been used to treat hypertensive renal damage (HRD) for over 20 years. Network pharmacology was used to determine whether YGYSG affects HRD via the autophagy pathway, which was verified using in vitro experiments.Material and methods: Common targets of YGYSG, HRD, and the autophagy pathway were screened using network pharmacology, and effective compounds, core targets, and signaling pathways were identified. The affinity of the compounds for the core targets was evaluated using molecular docking simulations. Angiotensin II (Ang II) was used to generate an in vitro renal podocyte model using MPC-5 cells. Morphological changes in the autophagosomes were observed using transmission electron microscopy (TEM). The expression levels of autophagy-related and pathway proteins were detected using western blotting and reverse transcription quantitative real-time PCR (PCR).Results: Network pharmacology and molecular docking analyses identified eight autophagy-related core targets and ten core components in the YGYSG treatment of HRD. These targets are mainly involved in the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signaling pathway and autophagy-related biological processes. In vitro experiments showed that Ang II-stimulated renal podocytes exhibited abnormal autophagy, and YGYSG protected renal podocytes from abnormal autophagy. In addition, YGYSG reversed abnormal autophagy and improved HRD by activating the PI3K/AKT/mTOR signaling pathway.Conclusions: YGYSG may regulate abnormal autophagy in renal podocytes by activating the PI3K/AKT/mTOR signaling pathway and may play a role in improving HRD.